Nigeria seizes 1,600 birds at Lagos airport bound for Kuwait

Customs officials at Nigeria's Lagos international airport said they had seized more than 1,600 parrots and canaries that were being transported to Kuwait without a permit, in one of the biggest such seizures in years. (AP/File)
Short Url
Updated 05 August 2025
Follow

Nigeria seizes 1,600 birds at Lagos airport bound for Kuwait

  • The cargo of live birds was intercepted by customs officials at the airport on July 31
  • Parrots, songbirds and birds of prey are among the most trafficked birds for the exotic pet trade

LAGOS: Customs officials at Nigeria’s Lagos international airport said they had seized more than 1,600 parrots and canaries that were being transported to Kuwait without a permit, in one of the biggest such seizures in years.

The cargo of live birds, which included ring-necked parakeets and yellow-fronted canaries, was intercepted by customs officials at the airport on July 31, the agency said in a statement late on Monday.

Nigeria, which has become a transit hub for trafficking in wildlife and wildlife products, is a signatory to the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES).

Parrots, songbirds and birds of prey are among the most trafficked birds for the exotic pet trade, private collections and for feathers or trophies, according to the United Nations 2024 World Wildlife Report.

Michael Awe, a customs controller at Lagos airport, said the birds were not accompanied by a CITES permit and other documents required to prove they were legally obtained.

“No illegal shipment will slip through the cracks under my watch at the airport, because the eagle eyes of my command officers are everywhere to detect and intercept,” he said in the statement.

Awe said customs were investigating those responsible for the illicit cargo, adding that the birds would be handed over to the National Parks Service.


EU regulator backs approval for Moderna’s combined COVID and flu vaccine

Updated 3 sec ago
Follow

EU regulator backs approval for Moderna’s combined COVID and flu vaccine

  • Currently people need two separate shots to protect them against COVID-19 and influenza
  • Moderna is banking on the COVID-flu combination shot

BRUSSELS: Europe’s medicines regulator recommended approval for Moderna’s COVID and flu combination vaccine on Friday, putting it on track to become the first single shot to protect people aged 50 and older against both illnesses.
Currently people need two separate shots to protect them against COVID-19 and influenza and the vaccines are updated regularly to match the viral strains in circulation.
Moderna is banking on the COVID-flu combination shot and also an mRNA-based flu shot to help it return ⁠to revenue growth as demand ⁠for COVID vaccines has collapsed in the years after the pandemic.
It hopes international markets will drive revenue growth this year, as anti-vaccine activist US Health Secretary Robert F. Kennedy Jr has disrupted the domestic market.

MODERNA SHARES HAVE PLUNGED FROM 2021 HIGHS
Shares of the biotech, which were flat in US premarket hours on Friday, have declined by ⁠nearly 90 percent from 2021 highs.
Last year, Moderna withdrew its US application for its COVID-flu combination shot to wait for efficacy data from a late-stage trial of its influenza vaccine.
Earlier this month, the company said it was waiting for guidance from the Food and Drug Administration on refiling the application.
US regulators initially refused to review a separate mRNA-based flu vaccine from the company, then reversed course a week later after Moderna amended its application.
EMA’s recommendation on Friday was based on data from a study of 8,000 participants that showed those who ⁠received mCombriax generated more ⁠antibodies than those who received separate shots against the viruses.
The study compared mCombriax with a combination of Moderna’s COVID-19 shot Spikevax and traditional flu shots from GSK and Sanofi.
EMA also considered data from a study of a similar mRNA flu vaccine, in which mCombriax triggered an adequate immune response. The shot contains messenger RNA with instructions for making proteins found on some strains of the influenza virus and SARS-CoV-2.
EMA’s recommendation will be reviewed by the European Commission, which will give the final sign off for marketing in the European Union. It was not clear how long that decision would take.